Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome

Jong Hyeon Ahn, Minkyeong Kim, Ji Sun Kim, Jinyoung Youn, Wooyoung Jang, Eungseok Oh, philhyu Lee, Seong Beom Koh, Tae Beom Ahn, Jin Whan Cho

Research output: Contribution to journalArticle

Abstract

Introduction: In the present study, midbrain atrophy and the pons-to-midbrain area ratio (P/M ratio) were investigated as diagnostic markers for presymptomatic progressive supranuclear palsy-Richardson's syndrome (Pre-PSP-RS). Methods: The present study included 27 patients with probable PSP-RS who underwent brain MRI at least twice before and after the development of clinical symptoms, age- and sex-matched participants with Parkinson's disease (PD, n = 27), and healthy controls (n = 27). The midbrain area, pons area, and P/M ratio of the Pre-PSP-RS, PD, and control subjects were measured using midsagittal images from brain MRI, and the parameters were compared among the groups. Results: The midbrain area decreased and the P/M ratio increased significantly in the Pre-PSP-RS patients compared with both the PD and control subjects (midbrain, Pre-PSP-RS vs. PD = 1.01 cm2 vs. 1.29 cm2, p < 0.001, Pre-PSP-RS vs. controls = 1.01 cm2 vs. 1.29 cm2, p < 0.001; P/M ratio, Pre-PSP-RS vs. PD = 5.27 vs. 4.03, p < 0.001, Pre-PSP-RS vs. controls = 5.27 cm2 vs. 4.06 cm2, p < 0.001). The P/M ratio had high sensitivity (vs. PD, 96.3%, vs. control, 88.9%) and specificity (vs. PD, 81.5%, vs. control, 96.3%) in differentiating Pre-PSP-RS patients from PD and control subjects. Conclusion: Midbrain atrophy precedes the clinical symptoms of PSP-RS and could be a useful diagnostic imaging biomarker for Pre-PSP-RS. Furthermore, this information could play an important role in the development of future treatment strategies.

Original languageEnglish
JournalParkinsonism and Related Disorders
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Progressive Supranuclear Palsy
Mesencephalon
Atrophy
Pons

All Science Journal Classification (ASJC) codes

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Ahn, Jong Hyeon ; Kim, Minkyeong ; Kim, Ji Sun ; Youn, Jinyoung ; Jang, Wooyoung ; Oh, Eungseok ; Lee, philhyu ; Koh, Seong Beom ; Ahn, Tae Beom ; Cho, Jin Whan. / Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome. In: Parkinsonism and Related Disorders. 2019.
@article{fbcd8c24205449e89a9f947c9624de38,
title = "Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome",
abstract = "Introduction: In the present study, midbrain atrophy and the pons-to-midbrain area ratio (P/M ratio) were investigated as diagnostic markers for presymptomatic progressive supranuclear palsy-Richardson's syndrome (Pre-PSP-RS). Methods: The present study included 27 patients with probable PSP-RS who underwent brain MRI at least twice before and after the development of clinical symptoms, age- and sex-matched participants with Parkinson's disease (PD, n = 27), and healthy controls (n = 27). The midbrain area, pons area, and P/M ratio of the Pre-PSP-RS, PD, and control subjects were measured using midsagittal images from brain MRI, and the parameters were compared among the groups. Results: The midbrain area decreased and the P/M ratio increased significantly in the Pre-PSP-RS patients compared with both the PD and control subjects (midbrain, Pre-PSP-RS vs. PD = 1.01 cm2 vs. 1.29 cm2, p < 0.001, Pre-PSP-RS vs. controls = 1.01 cm2 vs. 1.29 cm2, p < 0.001; P/M ratio, Pre-PSP-RS vs. PD = 5.27 vs. 4.03, p < 0.001, Pre-PSP-RS vs. controls = 5.27 cm2 vs. 4.06 cm2, p < 0.001). The P/M ratio had high sensitivity (vs. PD, 96.3{\%}, vs. control, 88.9{\%}) and specificity (vs. PD, 81.5{\%}, vs. control, 96.3{\%}) in differentiating Pre-PSP-RS patients from PD and control subjects. Conclusion: Midbrain atrophy precedes the clinical symptoms of PSP-RS and could be a useful diagnostic imaging biomarker for Pre-PSP-RS. Furthermore, this information could play an important role in the development of future treatment strategies.",
author = "Ahn, {Jong Hyeon} and Minkyeong Kim and Kim, {Ji Sun} and Jinyoung Youn and Wooyoung Jang and Eungseok Oh and philhyu Lee and Koh, {Seong Beom} and Ahn, {Tae Beom} and Cho, {Jin Whan}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.parkreldis.2019.07.009",
language = "English",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",

}

Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome. / Ahn, Jong Hyeon; Kim, Minkyeong; Kim, Ji Sun; Youn, Jinyoung; Jang, Wooyoung; Oh, Eungseok; Lee, philhyu; Koh, Seong Beom; Ahn, Tae Beom; Cho, Jin Whan.

In: Parkinsonism and Related Disorders, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome

AU - Ahn, Jong Hyeon

AU - Kim, Minkyeong

AU - Kim, Ji Sun

AU - Youn, Jinyoung

AU - Jang, Wooyoung

AU - Oh, Eungseok

AU - Lee, philhyu

AU - Koh, Seong Beom

AU - Ahn, Tae Beom

AU - Cho, Jin Whan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: In the present study, midbrain atrophy and the pons-to-midbrain area ratio (P/M ratio) were investigated as diagnostic markers for presymptomatic progressive supranuclear palsy-Richardson's syndrome (Pre-PSP-RS). Methods: The present study included 27 patients with probable PSP-RS who underwent brain MRI at least twice before and after the development of clinical symptoms, age- and sex-matched participants with Parkinson's disease (PD, n = 27), and healthy controls (n = 27). The midbrain area, pons area, and P/M ratio of the Pre-PSP-RS, PD, and control subjects were measured using midsagittal images from brain MRI, and the parameters were compared among the groups. Results: The midbrain area decreased and the P/M ratio increased significantly in the Pre-PSP-RS patients compared with both the PD and control subjects (midbrain, Pre-PSP-RS vs. PD = 1.01 cm2 vs. 1.29 cm2, p < 0.001, Pre-PSP-RS vs. controls = 1.01 cm2 vs. 1.29 cm2, p < 0.001; P/M ratio, Pre-PSP-RS vs. PD = 5.27 vs. 4.03, p < 0.001, Pre-PSP-RS vs. controls = 5.27 cm2 vs. 4.06 cm2, p < 0.001). The P/M ratio had high sensitivity (vs. PD, 96.3%, vs. control, 88.9%) and specificity (vs. PD, 81.5%, vs. control, 96.3%) in differentiating Pre-PSP-RS patients from PD and control subjects. Conclusion: Midbrain atrophy precedes the clinical symptoms of PSP-RS and could be a useful diagnostic imaging biomarker for Pre-PSP-RS. Furthermore, this information could play an important role in the development of future treatment strategies.

AB - Introduction: In the present study, midbrain atrophy and the pons-to-midbrain area ratio (P/M ratio) were investigated as diagnostic markers for presymptomatic progressive supranuclear palsy-Richardson's syndrome (Pre-PSP-RS). Methods: The present study included 27 patients with probable PSP-RS who underwent brain MRI at least twice before and after the development of clinical symptoms, age- and sex-matched participants with Parkinson's disease (PD, n = 27), and healthy controls (n = 27). The midbrain area, pons area, and P/M ratio of the Pre-PSP-RS, PD, and control subjects were measured using midsagittal images from brain MRI, and the parameters were compared among the groups. Results: The midbrain area decreased and the P/M ratio increased significantly in the Pre-PSP-RS patients compared with both the PD and control subjects (midbrain, Pre-PSP-RS vs. PD = 1.01 cm2 vs. 1.29 cm2, p < 0.001, Pre-PSP-RS vs. controls = 1.01 cm2 vs. 1.29 cm2, p < 0.001; P/M ratio, Pre-PSP-RS vs. PD = 5.27 vs. 4.03, p < 0.001, Pre-PSP-RS vs. controls = 5.27 cm2 vs. 4.06 cm2, p < 0.001). The P/M ratio had high sensitivity (vs. PD, 96.3%, vs. control, 88.9%) and specificity (vs. PD, 81.5%, vs. control, 96.3%) in differentiating Pre-PSP-RS patients from PD and control subjects. Conclusion: Midbrain atrophy precedes the clinical symptoms of PSP-RS and could be a useful diagnostic imaging biomarker for Pre-PSP-RS. Furthermore, this information could play an important role in the development of future treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=85068734654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068734654&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2019.07.009

DO - 10.1016/j.parkreldis.2019.07.009

M3 - Article

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -